On March 3, 2011, the US Food and Drug Administration (FDA)1 announced that companies that manufacture, distribute, or market approximately 500 unapproved prescription oral cough, cold, and allergy drugs must cease doing so. Although companies that were not listed with the FDA had to stop manufacturing and shipping such drugs immediately, those companies listed with the FDA had to stop manufacturing the unapproved drugs by June 3, 2011, and shipping by September 3, 2011. The reasons the FDA took this action are stated in the comprehensive Commentary by Ostroff et al2 in this issue of CHEST (see page 295). In short, because none of the banned medications had undergone the safety and effectiveness evaluation process of the FDA, the FDA could not be certain how they were manufactured, what was contained within them, or whether they would work as advertised. We applaud the FDA for taking this action and for contacting us, the developers and publishers of the American College of Chest Physicians (ACCP) Cough Guidelines,3 before their announcement to learn if we thought that there might be any potential unintended consequences of their action on managing patients with cough.